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MiceIn this study, the antinociceptive, anti-hypernociceptive and toxic effects of orally administered (R)-Se-
phenyl thiazolidine-4-carboselenoate (Se-PTC, 1–50 mg/kg) were evaluated in mice. Se-PTC did not change
plasma aspartate (AST) and alanine aminotransferase (ALT) activities or urea and creatinine levels.
Furthermore, in an open ﬁeld test, Se-PTC did not alter the number of crossings and rearing. Se-PTC
signiﬁcantly reduced the amount of writhing when assessed by acetic acid-induced visceral nociception and
attenuated the licking time of the injected paw in the early and late phases of a formalin test. In addition, Se-
PTC reduced nociception produced by intra-plantar (i.pl.) injection of glutamate, capsaicin, cinnalmaldehyde,
bradykinin, phorbol myristate acetate and 8-Bromo-cAMP. Se-PTC caused a signiﬁcant increase in hot plate
and tail-immersion response latencies, but the antinociceptive effect of Se-PTC in the tail immersion was not
abolished by pretreatment with the non-selective opioid receptor antagonist, naloxone. Se-PTC (25 mg/kg)
signiﬁcantly inhibited nociceptive behavior induced by intrathecal (i.t.) injection of glutamate, N-methyl-D-
aspartate (NMDA) and (±)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), but failed to
affect nociception induced by kainate and α-amino-3-hydroxy-5-mehtyl-4-isoxazolepropionic acid (AMPA).
Mechanical hypernociception induced by carrageenan and Complete Freund's Adjuvant was attenuated by Se-
PTC administration. These results indicate that Se-PTC produces antinociception in several models of
nociception.elotas-UFPEL, CEP 96010-900,
Savegnago).
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Pain is an essential sensation that usually signals tissue injury
inﬂicted by external or internal damaging events. Frequently, tissue
damage leads to activation of nociceptors through the release of a
variety of chemical mediators, such as excitatory amino acids, protons,
peptides, lipids and cytokines, among others, which act on speciﬁc
receptors and ion channels, activating various signal transduction
cascades, contributing to the induction of pain (Sawynok, 2003). It is
accepted that the sensitization of primary nociceptive neurons is the
common denominator in inﬂammatory pain that leads to states known
as hyperalgesia/allodynia in humans or hypernociception in animal
models (Cunha et al., 2005; Verri et al., 2006). Hypernociception is
induced by the action of inﬂammatory mediators, such as prostaglan-dins and sympathetic amines, on peripheral nociceptors. These direct
acting hyperalgesic mediators are ultimately released into the inﬂamed
tissue following a cascade of cytokines, including tumor necrosis
factor-α, interleukin-1β, bradykinin, glutamate and chemokines,
which are released by the resident and migratory cells (Cunha et al.,
2005; Verri et al., 2006). The identiﬁcation of compounds that can
effectively treat painful states without the induction of side-effects
remains a major challenge in biomedical research (Whittle, 2003).
In this context, thiazolidines and their derivates are widely known
as analgesics and for their anti-inﬂammatory effects (Vigorita et al.,
2003). Thiazolidines, such as rosiglitazone and pioglitazone, are
synthetic compounds that bind and activate PPARγ. They share a
common structure that is responsible for the majority of their phar-
macological effects, including anti-inﬂammatory effects (Yi et al.,
2008). Moreover, another compound, (2R,2VS) 3,3V-(1,2-ethanediyl)
bis[2-(3,4-dimethoxyphenyl)-thiazolidin-4-one] (VIG3b), had a
promising anti-inﬂammatory activity in the experimental model of
carrageenan-induced lung injury (Ottaná et al., 2002).
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inﬂammatory activities of Se-PTC, an organoselenium compound
containing a thiazolidine ring. Selenium is an integral part of functional
selenoproteins, including glutathione peroxidase and thioredoxin
reductase, which catalyze reactions essential for the protection of
cellular components against oxidative and free radical damage (Bock et
al., 1991). In previous publications we reported on the pharmaceutical
potential of organoselenium compounds, especially the antinociceptive
and anti-inﬂammatory properties (Jesse et al., 2007, 2008, 2009a,b,c;
Luchese et al., 2010; Pinto et al., 2008; Savegnago et al., 2006, 2007a,b,c;
Wilhelm et al., 2009), which are potentially useful drugs for pain
management. The aims of the present study were to evaluate: (a) the
toxicity of orally administered Se-PTC; (b) the antinociceptive effect
induced by Se-PTC in different models of acute nociception; (c) the
involvement of the opioid system in the Se-PTC antinociceptive effect
and (d) the anti-hypernoceptive effect of Se-PTC.
2. Materials and methods
2.1. Drugs
Se-PTC [(R)-Se-phenyl thiazolidine-4-carboselenoate; Fig. 1] was
prepared and characterized as previously described (Braga et al.,
2005a,b; Rampon et al., 2010). The 1H NMR and 13C NMR spectra were
in full agreement with its assigned structure. Se-PTC was dissolved in
canola oil and administered by intragastric gavage in a single dose.
All other drugs were dissolved in a 0.9% saline solution, with the
exception of capsaicin, which was prepared in absolute ethanol (ﬁnal
concentrationb0.5%).
2.2. Animals
The experiments were conducted using male Swiss mice (25–35 g)
maintained at 22±2 °Cwith free access towater and food, under a 12 h
light/dark cycle (with lights on at 6:00 a.m.). Mice were acclimatized to
the laboratory for at least 1 h before testing and were used only once
during the experiments. All experiments were carried out according to
the Guide for the Care and Use of Laboratory Animals, U.S. Department
of Health and Human Services (NIH publication no. 85–23, revised
1985) and the ethical guidelines for investigations of experimental pain
in conscious animals (Zimmermann, 1983). Additionally, the Commit-
tee on Care and Use of Experimental Animal Resources, Federal
University of Pelotas, Brazil approved the protocols used in this study.
The number of animals and the intensity of noxious stimuli used were
kept to theminimumnecessary to demonstrate the consistent effects of
the drug treatments. After experiments, animals were euthanized by
cervical displacement.
2.3. Acute toxicity
To investigate the potential acute toxicity caused by Se-PTC, the
mice received a single oral dose of Se-PTC (1–50 mg/kg) or vehicle
(canola oil, 10 ml/kg). The animals were observed for up to 72 h,
anesthetized prior to blood collection by heart puncture into heparin
containing tubes. Plasma was obtained by centrifugation at 2000×g
for 10 min (hemolyzed plasma was discarded) and used for the
biochemical assays. Plasma aspartate (AST) and alanine aminotrans-S
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Fig. 1. Chemical structure of (R)-Se-phenyl thiazolidine-4-carboselenoate (Se-PTC).ferase (ALT) activities, used as biochemical markers for early acute
hepatic damage, were determined by the colorimetric method of
Reitman and Frankel (1957). Renal function was analyzed by
determining plasma urea (Mackay and Mackay, 1927) and creatinine
levels (Jaffe, 1886).
2.4. Open ﬁeld task
Thirtyminutes after oral administration of the Se-PTC (1–50 mg/kg,
p.o.) or canola oil (control group), the mice were evaluated indi-
vidually in an open ﬁeld task. Each animal was placed at the center of
the apparatus and observed for 10 min to record any spontaneous
ambulation (number of segments crossed with the four paws) and
exploratory activity (number of times reared on the hind limbs)
(Walsh and Cummins, 1976). The open ﬁeld task apparatus was
constructed from plywood, the walls were 30 cm in height, the ﬂoor
measured 45×45 cm, and was divided into 9 squares (3×3) using
masking tape.
2.5. Chemical models of nociception
2.5.1. Acetic acid-induced abdominal constriction
The abdominal constriction was induced as described previously
by Corrêa et al. (1996) and resulted in contraction of the abdominal
muscle together with stretching of the hind limbs in response to an
intraperitoneal injection (i.p.) of acetic acid (1.6%). Mice were
pretreated with Se-PTC (1–50 mg/kg), via the peroral route (p.o),
0.5 h before injection with acetate. Control animals received a similar
volume of the vehicle (10 ml/kg, canola oil) as the negative, or
Celecoxib (150 mg/kg, p.o.) as the positive control. Post-challenge, the
mice were placed individually into separate boxes and the total
number of abdominal constrictions were counted over a period of
20 min. Antinociceptive activity was expressed as the reduction in the
number of abdominal constrictions compared to the negative control
group. To assess the time-course of the antinociceptive effect, mice
were pretreated with Se-PTC (50 mg/kg, p.o.) 0.5–6 h before injection
of the acetic acid.
2.5.2. Formalin induced nociception
The formalin test was carried out as described by Hunskaar and
Hole (1987). Brieﬂy, formalin was administed by intraplantar (i.pl.)
injection (2.5%, 20 μL, v/v) into the mouse dorsal right hind paw. The
mice were returned to the experimental cage and the time spent
licking or biting the injected paw was recorded during the ﬁrst 5 min
and 15–30 min post-i.pl., early and late phase, respectively. Se-PTC
(1–50 mg/kg, p.o.), the vehicle (canola oil, p.o., 10 ml/kg), or
Celecoxib (150 mg/kg, p.o.), were administrated 0.5 h before formalin
administration.
2.5.3. Glutamate-induced nociception
The procedure used was similar to that described previously
(Beirith et al., 2002). Mice were treated with Se-PTC (1–50 mg/kg,
p.o.), vehicle (canola oil, p.o., 10 ml/kg) or Celecoxib (150 mg/kg, p.o.),
0.5 h before i.pl. injection of glutamate (10 μmol, 20 μL) into the
mouse dorsal right hind paw. The mice were observed for 15 min
post-injection and the time spent licking the injected paw was
recorded and considered as a nociceptive behavior.
In a further experiment, the interaction of Se-PTC with the
glutamatergic system was investigated by using both ionotropic and
metabotropic agonists of excitatory amino acid receptors, which were
administered by the intrathecal (i.t.) route and causes biting behavior in
mice. Animals received Se-PTC (25 mg/kg, p.o) 0.5 h before i.t. injection
of 5 μL of the agonists. [(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]
cyclohepten-5,10-iminemaleate)] (MK-801) (0.5 mg/kg, i.p.) was used
as positive control andwas pre-administered 0.5 h before the glutamate
injection. Injectionswere administered to fully consciousmice using the
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were restrained manually and a 30-gage needle, attached to a 50 μL
microsyringe, was inserted through the skin and between the vertebrae
into the subdural space of the L5–L6 spinal segments. Biting behavior
was deﬁned as a single headmovement directed toward the lumbar and
caudal region of spinal cord or hind limbs, resulting in contact of the
animal's snout with the target organ. Intrathecal injections were given
over a period of 5 s. The nociceptive response was elicited by glutamate
(175 nmol/site, i.t.), AMPA (a selective agonist of AMPA-subtype of
glutamatergic ionotropic receptors, 135 pmol/site, i.t.) (Brambilla et al.,
1996), NMDA (a selective agonist of NMDA-subtype of glutamatergic
ionotropic receptors, 450 pmol/site, i.t) (Urca and Raigorodsky, 1998),
kainate (a selective agonist of kainate-subtype of glutamatergic
ionotropic receptors, 110 pmol/site, i.t.) or trans-ACPD (an agonist of
metabotropic glutamate receptors, 50 nmol/site, i.t) (Boxall et al., 1998).
In the negative control group, mice received the vehicle (saline) by the
i.t. route. The amount of time the mice spent biting the target organ
was evaluated following the injection of one of the following agonists:
glutamate 3 min; AMPA 1 min; NMDA 5 min; kainate 4 min or trans-
ACPD 15 min.
2.5.4. Capsaicin, Cinnalmaldehyde, Bradykinin, 8-Bromo-cAMP, Phorbol
myristate acetate-induced nociception
Mice were pretreated with Se-PTC (1–50 mg/kg, p.o.), vehicle
(canola oil, p.o., 10 ml/kg) or Celecoxib (150 mg/kg, p.o.), 0.5 h before
the i.pl. injection of 20 μL of capsaicin (1.6 μg/paw) (Sakurada et al.,
1993), cinnalmaldehyde (10 nmol/paw) (Andrade et al., 2008),
bradykinin (10 nmol/ paw) (Ferreira et al., 2004), 8-Bromo-cAMP
(10 nmol/paw) (Otuki et al., 2005) or phorbol myristate acetate
(0.03 μg/paw) (Ferreira et al., 2005) into the ventral surface of the
right hind paw. The amount of time spent licking the injected pawwas
recorded following the injection of one of the following: capsaicin and
cinnalmaldehyde 5 min, bradykinin and 8-Bromo-cAMP 10 min or
phorbol myristate acetate 0.5 h.
2.6. Thermal models of nociception
2.6.1. Hot-plate test
The hot-plate test was carried out as described by Woolfre and
MacDonald (1944). In this test, the animals were placed in a glass
cylinder on a heatedmetal plate maintained at 55±1 °C. The latency of
the nociceptive responses such as licking or shaking one of the paws
or jumping was recorded as the reaction time. Mice were treated with
Se-PTC (1–50 mg/kg, p.o.) or vehicle (canola oil, p.o., 10 ml/kg). The
change in thermal withdrawal latencies was recorded before treatment
and at 0.5 h after treatment with Se-PTC. The delta latency, Δt (s) was
calculated for each animal according to the formula: Δt (s)=post-drug
latency−pre-drug latency. In order to avoid damage to the paws of the
animals, the time standing on the plate was limited to 30 s.
2.6.2. Tail-immersion
The tail-immersion test was carried out as described by Janssen et
al. (1963). Brieﬂy, a 3.5 cm portion at the tip of the tail was marked
and immersed into a cup ﬁlled with water at 55 °C until the typical tail
withdrawal response was observed. The animal groups were pre-
treated with Se-PTC (1–50 mg/kg, p.o) or with the vehicle in theTable 1
Effect of Se-PTC administered orally on biochemical parameters and on the locomotor activ
Grups (mg/kg) AST (U/L) ALT (U/L) Urea (mg/d
Control 143.7±28.27 60.87±25.65 44.72±7.83
1 148.2±27.78 63.00±23.53 43.78±6.84
10 148.6±25.45 60.81±17.84 43.22±7.08
25 148.1±23.10 61.21±19.42 32.20±6.76
50 135.0±18.89 64.47±29.77 37.17±5.38
Data are reported as means±S.E.M of six animals.control group. A 7 s cut-off was applied to this test. Changes in tail-
ﬂick latency, Δt (s), were calculated for each animal according to the
formula: Δt (s)=post-drug latency−pre-drug latency as previously
reported (Pinardi et al., 2003).
The possible participation of the opioid system in the antinocicep-
tive effect caused by Se-PTC in the tail-immersion test was investi-
gated. Selectedmicewere pre-treatedwith naloxone (5 mg/kg, s.c.) or
saline (0.9% NaCl), 15 min before administration of vehicle (canola oil,
p.o.,10 ml/kg), morphine (2.5 mg/kg, s.c., positive control) or Se-PTC
(50 mg/kg, p.o.).
2.7. Mechanical model of hypernociception
2.7.1. Mechanical hypernociception induced by Carrageenan and
Complete Freund's adjuvant
For the induction of inﬂammatory nociception, mice received an
i.pl. injection of 50 μL of carrageenan (300 μg/paw) and to produce a
persistent inﬂammatory response, animals received a 20 μL i.pl.
injection of Freund's Complete adjuvant (1 mg/ml heat-killed and
dried Mycobacterium tuberculosis; each ml of vehicle contained
0.85 ml parafﬁn oil plus 0.15 ml mannide monooleate) under the
surface of the right hind paw (Quintão et al., 2005). Mice that
presentedwithmechanical hypernociception received either a dose of
the vehicle (canola oil, p.o., 10 ml/kg) or Se-PTC (50 mg/kg, p.o.). The
withdrawal response frequency in Von Frey ﬁlament was recorded
0.5, 1, 2, 4 and 6 h post-treatment. The frequency of withdrawal was
determined before (baseline) the carrageenan or Complete Freund's
Adjuvant injections, in order to obtain data derived solely from the
carrageenan and Complete Freund's Adjuvant hypernociception.
Mechanical hypernociception in mice with carrageenan and Complete
Freund's Adjuvant were measured by using a calibrated nylon Von
Frey ﬁlament of 0.6 g.
2.8. Statistical analysis
The results are presented as mean±S.E.M., except for the ID50
values (i.e., the dose of Se-PTC producing half maximal antinocicep-
tive or the dose necessary to reduce the nociceptive response by 50%
relative to the control value). The ID50 values were determined by
graphical interpolation from individual experiments and are reported
as geometric means accompanied by their respective 95% conﬁdence
limits (GraphPad software, San Diego, CA, USA). Comparisons be-
tween the experimental and control groups were performed by
ANOVA followed by the Newman–Keuls' test where appropriate. P
values less than 0.05 (pb0.05) were considered signiﬁcant.
3. Results
3.1. Acute toxicity, locomotor and exploratory activities
No deaths were observed in mice following administration of Se-
PTC. Furthermore, p.o. administration of Se-PTC, at the doses tested
(1–50 mg/kg), did not alter plasma AST or ALT activities, or the urea
and creatinine levels when compared to the control group (Table 1).
No alteration in the locomotor or exploratory activities of the animals
treated with Se-PTC, was observed (Table 1).ity in mice.
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Fig. 2. Time-course of the antinociceptive effect of Se-PTC (50 mg/kg) on acetic acid-
induced writhing in mice (A). Dose related effect of Se-PTC in the acetic acid induced
writhing response in mice (B). Celecoxib (150 mg/kg, p.o.) was used as a positive control.
Each line represents the mean with S.E.M. for 5–7 mice in each group. Control value “C”
indicates the animals injected with vehicle only (canola oil). The asterisks denote
the signiﬁcance levels when compared with the control group: * — Pb0.05; ** — Pb0.01
and ***— Pb0.001. The hash symbol (#) denotes the signiﬁcance levelswhen compared to
other groups: Pb0.05. Statistical analysis was carried out using one-way ANOVA followed
by the Newman–Keuls test.
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A time-course analysis of the antinociceptive effect of Se-PTC was
accomplished using the acetic-acid test. The antinociceptive effect of
Se-PTC peaked after 0.5 h and remained signiﬁcant for up to 4 h
(Fig. 2A), therefore this time point (0.5 h) was chosen for all further
studies. The maximal inhibition values observed were 62±5% (0.5 h),
38±4% (1 h), 35±3% (2 h) and 20±3% (4 h).
The results of the antinociceptive effect of different doses of Se-PTC
on the acetic acid-induced abdominal constriction response in mice
are presented in Fig. 2B. It can be seen that Se-PTC given (0.5 h earlier)
by the p.o. route, inhibited the acetic acid-induced abdominal
constriction response in mice, the mean ID50 value was 26.41 (6.14–
46.68) mg/kg and the maximal inhibitory effect was 65±4%. Pre-
treatment with celecoxib (positive control) reduced the acetic acid-
induced abdominal constriction response by up to 55±4% (Fig. 2B).Table 2
Effect of Se-PTC on the licking induced by intraplantar injection of formalin, glutamate, cap
Dose of Se-PTC
(mg/kg)
Formalin test Glutamate Capsaici
First phase Second phase
Control 96.7±5.63 182.0±11.98 122.5±11.41 94.5±3
1 90.57±10.90 133.6 ±11.20a 104.2±13.02 85.8±1
10 73.83 ±12.54 98.5±13.61c 87.2±11.92 57.7±5
25 50.4±8.03b 44.8±6.22c 71.4±9.74a 44.2±5
50 41.2±5.22b 44.1±6.06c 45.8±10.23c 32.3±4
Celecoxib 56.6±4.65c 64.5±7.98c 74.8±11.21a 48.9±5
Values are means±S.E.M. of 5–7 mice.
aPb0.05, bPb0.01, cPb0.001 versus control group (one-way ANOVA followed by Newman–
Celecoxib (positive control) was administered at the dose of 150 mg/kg (p.o.).Se-PTC pre-treatment signiﬁcantly inhibited both neurogenic (0 to
5 min) and inﬂammatory (15 to 30 min) phases of the formalin-
induced licking response, Table 2. The mean ID50 values for
neurogenic and inﬂammatory nociception were 34.78 (27.92–41.64)
and 9.58 (4.88–14.28) mg/kg, respectively, while the maximal
inhibitory effects observed were 58±5% and 76±4%, respectively.
Administration of the positive control (celecoxib 150 mg/kg, p.o.)
reduced the acetic acid-induced abdominal constriction in mice with
maximal inhibitory effect of 55±4% (Fig. 2B).
The results presented in Table 2 show that Se-PTC, administered
orally, caused a signiﬁcant inhibition of glutamate-induced nocicep-
tion, with a mean ID50 value of 32.19 (17.15–47.23)mg/kg and an
inhibitory effect of 63±5%. The positive inhibited the glutamate-
induced licking response by up to 39±6%.
Se-PTC attenuated capsaicin-induced neurogenic nociception in
mice (Table 2). Themean ID50 was 23.22 (11.43–35.01)mg/kg and the
inhibitory effect was 66±6%. Celecoxib administration reduced
capsaicin-induced nociceptive behavior by up to 49±4%.
Pre-treatment with Se-PTC resulted in attenuation of cinnamalde-
hyde-induced neurogenic nociception in mice (Table 2). The mean
ID50 value was 20.98 (15.25–26.71)mg/kg and inhibitionwas 69±7%.
The positive control reduced cinnamaldehyde-induced nociceptive
response by 51±3%.
Table 2 shows that Se-PTC caused signiﬁcant inhibition of
nociception induced by bradykinin. The mean ID50 value for
nociception was 25.98 (17.25–34.71)mg/kg and the maximal inhib-
itory effect observed was 77±5%. The positive control inhibited the
bradykinin-induced nociceptive response by 45±5%.
The results presented in Table 2 show that Se-PTC (5–50 mg/kg)
resulted in a signiﬁcant inhibition (76±5%) of phorbol myristate
acetate -induced nociception. The mean ID50 value for nociception
was 12.35 (8.78–15.92)mg/kg. Oral administration of celecoxib
(positive control, 150 mg/kg) diminished the phorbol myristate
acetate-induced nociceptive response by 51±3%.
Se-PTC treatment (25–50 mg/kg) inhibited the 8-Br-cAMP in-
duced licking response, by up to 60±4%, (Table 2). The mean ID50
value for nociception was 11.36 (8.55–14.17)mg/kg. Administration
of the positive control reduced the 8-Br-cAMP-induced nociceptive
response by 47±3%.
3.3. Effect of Se-PTC on thermal models of nociception in mice
In the hot plate test, Se-PTC, at doses of 10–50 mg/kg, caused a
signiﬁcant increase in the latency response to thermal stimuli
compared to the control group (Fig. 3A). In the tail-immersion test,
pre-treatment with Se-PTC at doses of 25 and 50 mg/kg increased the
delta latency response compared to the control group (Fig. 3B).
Administration of morphine (positive control, 2.5 mg/kg, s.c.) in-
creased the delta latency in both hot plate and tail-immersion tests
compared to control group (Fig. 3A and B).
The possible involvementof the opioid system in the antinociceptive
effect of Se-PTC was examined. Pretreatment with naloxone (5 mg/kg,saicin, cinnamaldeyde, bradykinin, PMA or 8-Br-cAMP in mice.
n Cinnamal-dehyde Bradykinin PMA 8-Br-cAMP
.08 63.2±2.47 52.5±5.66 196.8±16.91 57.1±5.70
0.51 64.5±5.02 44.6±4.20 160.6±15.85 66.2±8.72
.20b 49.8±8.76 28.3±3.25c 99.2±7.43c 48.75±10.22
.65c 28.8±4.59b 24.1±3.16c 79.4±6.91c 30.5±2.53a
.17c 19.8±6.14c 12.3±1.58c 46.8±8.20c 22.2±2.17b
.98c 31.5±5.65b 29.6±2.65c 85.6±12.35c 30.7±3.45a
Keul's test).
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Fig. 3. Effect of Se-PTC on the hot-plate (A) and tail-immersion (B) tests inmice. (C) Effect
of naloxone (5 mg/kg, s.c) or 0.9% saline, 15 min before administration of vehicle (canola
oil, p.o., 10 ml/kg), morphine (2.5 mg/kg, s.c.) or Se-PTC (50 mg/kg, p.o.) in the tail-
immersion test in mice. Morphine (2.5 mg/kg, s.c.) as positive control. Each column
represents the mean with S.E.M. for 6–10 mice in each group. Control value (C) indicates
the animals administered with vehicle (canola oil). The asterisks denote the signiﬁcance
levelswhencomparedwith control group: *—Pb0.05; **—Pb0.01and ***—Pb0.001. The
$ symbol denotes the signiﬁcance levelswhen compared tomorphinegroup: $— Pb0.001.
Statistical analysiswas carried out using one-way ANOVA followed by theNewman–Keuls
test.
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Fig. 4. Effect of Se-PTC administered orally (50 mg/kg) on mechanical hyperalgesia in
response to 10 applications of 0.6 g of Von Frey ﬁlament. Carrageenan in shown in (A) and
Complete Freund's Adjuvant is shown in (B). Celecoxib (150 mg/kg, p.o.) was used as a
positive control. Results represent the means±S.E.M. of eight animals. The symbols
denote a signiﬁcant difference: ** — Pb0.01 and *** — Pb0.001 between vehicle treated
and Se-PTC or celecoxib treatedmice and#— Pb0.001 versus baseline value (B). Statistical
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test.
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Fig. 5. Effect of Se-PTC administered orally (25 m/kg, p.o.) against glutamate
(175 nmol/site, i.t), NMDA (450 pmol/site, i.t.), AMPA (135 pmol/site, i.t.), kainate
(110 pmol/site, i.t.) or trans-ACPD (50 nmol/site, i.t.)-induced biting response in mice.
MK-801 (0.5 mg/kg, i.p.) was used as a positive control. Each column represents
the mean±S.E.M. for six to eight animals. Asterisks denote the signiﬁcance levels:
**— Pb0.01 and ***— Pb0.001 compared to the control group (solid columns). Statistical
analysis was carried out using one-way ANOVA followed by the Newman–Keuls test.
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of morphine (positive control) at the 2.5 mg/kg dose. The antinocicep-
tive effect of Se-PTC (50 mg/kg, p.o.)was not protected bypretreatment
with naloxone (Fig. 3C).
3.4. Effect of Se-PTC on mechanical models of hypernociception in mice
Carrageenan induced a marked mechanical hypernociception on
the ipsilateral side (Fig. 4A), but not on the contralateral side (data not
shown). Oral pretreatment of mice with Se-PTC (50 mg/kg) reduced,
by 48±4%, themechanical hypernociception induced by carrageenan,
an effect observed for up to 4 h at 50 m/kg (Fig. 4A). The positive
control inhibited the mechanical hypernociception induced by
carrageenan for up to 4 h (Fig. 4A).
Complete Freund's adjuvant induced mechanical hypernocicep-
tion on the ipsilateral side (Fig. 4B), but not on the contralateral side(data not shown) for up to 6 h. Pre-treatment with Se-PTC (50 mg/kg)
resulted in a signiﬁcant reduction (45±3%, for up to 4 h) in
mechanical hypernociception caused by Complete Freund's adjuvant
(Fig. 4B). In comparison, the positive control reduced (by howmuch?)
the mechanical hypernociception induced by Complete Freund 's
adjuvant for up to 4 h after the administration (Fig. 4B).
174 N.F. Pavin et al. / European Journal of Pharmacology 668 (2011) 169–1763.5. Spinal excitatory amino acids induced nociception-related behavior
in mice
The results presented in Fig. 5 show that Se-PTC (25 mg/kg),
caused signiﬁcant inhibition of the nociceptive response induced by
spinal injections of glutamate, NMDA or trans-ACPD, with maximal
inhibitory effect of 48±5, 61±6 and 47±5%, respectively. In
contrast, Se-PTC had no signiﬁcant effect against the AMPA and
kainate mediated biting response in mice. Administration of the
positive control (MK-801), reduced the nociceptive response induced
by spinal injection of glutamate, NDMA, AMPA, kainate or trans-ACPD
by 47±5%, 60±4%, 36±3%, 52±7% and 48±3%, respectively.
4. Discussion
The present study demonstrated, for the ﬁrst time, that oral
administration of Se-PTC induced antinociception responses in chem-
ical, thermal and mechanical models of nociception, without causing
acute toxicity or modifying the locomotor and exploratory activities in
mice. The data also found that Se-PTC did not alter plasma aspartate
(AST) and alanine aminotransferase (ALT) activity or urea and
creatinine levels, suggesting that Se-PTC is not nephro- or hepatotoxic.
Acetic acid, which induces writhing in mice, causes algesia by
liberation of endogenous substances, which excite the nerve endings
and induce pain. This nociception model has long been used to screen
for both peripherally and centrally acting agents (Tjolsen and Hole,
1997). However, the writhing test is not speciﬁc and cannot
discriminate between a central or peripheral antinociceptive effect.
In order to conﬁrm these effects a formalin testwas carried out. I.pl.
injection of dilute formalin in rodents produces a biphasic behavioral
response characteristic of pain. The short-lived initial response is
thought to be produced by direct activation of nociceptive neurons by
the formalin and the second phase is thought to be an inﬂammatory
response to tissue injury (Martindale et al., 2001). In this study, Se-PTC
inhibited both the ﬁrst and the second phase of the formalin-induced
nociception. Of the particular interest, dypirone, but not indomethacin
and acetaminophen inhibited the nociceptive response observed in the
ﬁrst phase of the formalin test (Abbott and Hellemans, 2000). Further-
more, dipyrone, indomethacin and acetaminophen produced antinoci-
ceptive effects on the second phase of the formalin test (Abbott and
Hellemans, 2000). Indeed, morphine (Shibata et al., 1989), organo-
selenium compounds (Luchese et al, 2010; Savegnago et al., 2007a) and
other non-steroidal anti-inﬂammatory drugs (NSAIDs) (Martindale
et al., 2001) were reported to inhibit nociception in both phases of the
formalin test.
Recent studies have shown that formalin activates the primary
afferent sensory neurons through a speciﬁc and direct action on the
transient receptor potential cation channel, member A1 (TRPA1),
which is highly expressed by a subset of the C-ﬁber nociceptors
(McNamara et al., 2007). In an evaluation of the role of TRPA1 in the
antinociceptive effect induced by Se-PTC, we found that Se-PTC
reduced the nociceptive response caused by cinnamaldehyde, a
TRPA1 agonist. This result is in agreement with that obtained in the
formalin test and suggests that Se-PTC may interact with TRPA1,
thereby reducing the formalin-induced nociception.
Based on these results, we sought to determine whether or not the
transient receptor potential vanilloid 1 (TRPV1) were involved in the
antinociceptive effect of Se-PTC observed in this study. Se-PTC inhibited
the spontaneousnociceptive response caused by capsaicin. In a previous
report, celecoxib, a known pyrazole compound, reduced nociception
induction by the TRPV1 agonist capsaicin (Oliveira et al., 2009). The
results reported in this study are consistent with previous ﬁndings by
our research group, in which diphenyl diselenide, p-metoxy-diphenyl
diselenide and 3-alkynyl selenophene caused signiﬁcant antinocicep-
tion against the capsaicin-induced licking response (Savegnago et al.,
2007a; Pinto et al., 2008; Wilhelm et al., 2009). Of note, it has beenwidely documented that capsaicin evokes the release of neuropeptides,
excitatory amino acids (glutamate and aspartate), nitric oxide and pro-
inﬂammatory mediators in the peripheral and transmits nociceptive
information to the spinal cord (Sakurada et al., 1996, 2003; Santos and
Calixto, 1997).
Glutamate is the major excitatory amino acid neurotransmitter
present in the central nervous system, where it participates in a great
diversity of biological functions, such as learning and memory,
neurodegenerative diseases and neuronal death. The nociceptive
response induced by glutamate is primarily mediated by the release of
neuropeptides from sensory ﬁbers, namely neurokinins and kinins
(Beirith et al., 2002). In addition, glutamate is found in sensory C ﬁbers
where it is believed to play a role in the transmission of nociceptive
mechanisms at the spinal cord (Hudspith, 1997). In order to provide
more evidence of glutamatergic systems involvement in the anti-
nociceptive of Se-PTC, we attempted to determine whether or not Se-
PTC was capable of inhibiting the nociceptive response caused by
selective glutamatergic receptor agonists. In agreement with previous
ﬁndings, Se-PTC caused a signiﬁcant inhibition of the glutamate,
NMDA e trans-ACPD induced biting response, but this was not
observedwith the AMPA and kainate agonists. Thus, together with the
present ﬁndings, there is evidence to suggest that the antinociceptive
action caused by Se-PTC depends on a selective interaction with the
NMDA and the trans-ACPD receptors. Previously we reported that
organoselenium compounds, such as diphenyl diselenide, p-methoxy-
diphenyl diselenide, bis selenide and 3-alkynyl selenophene inhibited
the nociceptive response induced in glutamate stimulated mice
(Savegnago et al., 2007a,c; Jesse et al., 2007, 2008; Pinto et al.,
2008; Wilhelm et al., 2009). In addition, aspirin and acetaminophen
demonstrated an antinociceptive effect in the glutamate test (Choi et
al., 2001).
There is now someevidence to suggest that glutamate acts onNMDA
and non-NMDA receptors, capsaicin-sensitiveﬁbers, neurokinin 1 and 2
and bradykinin (B1) receptors (Beirith et al., 2002; Ferreira et al., 1999).
Therefore, we investigated the participation of bradykinin in the
antinociceptive effect of Se-PTC. The results suggested that Se-PTC
abolished bradykinin-induced nociception. Bradykinin is an important
peripheral mediator of pain (Calixto et al., 2001), and once released,
bradykinin may cause pain by direct stimulation of the nociceptors (Aδ
and C ﬁbers) innervating many tissues. The action of bradykinin is
mediated through the stimulation of two subtypes of G-protein coupled
receptors, denoted B1 and B2 (Campos et al., 2006).
Ferreira et al. (2008) demonstrated that phorbol myristate acetate,
a known activator of protein kinase C, induced nociception is blocked
in B1 receptor knockout mice. Furthermore, several studies have
suggested a role for bradykinin and protein kinase C in the control of
pain sensitivity (Ferreira et al., 2005, 2008; Savegnago et al., 2007a). In
agreement, we demonstrated that Se-PTC inhibited phorbol myristate
acetate-induced nociception in mice. It is recognized that protein
kinase C activation is an important step for the nociceptive effects
caused by numerous stressful stimuli, including those caused by
inﬂammatory mediators. Protein kinase C can phosphorylate several
cellular components, including enzymes, ion channels and mem-
brane-bound receptors that are key regulators in the process of
nociceptor excitation and sensitization (Ji and Woolf, 2001). Based on
these results we can speculate that the antinociceptive effect caused
by Se-PTC is related to its ability to interact with protein kinase C and
pathway-B1 and B2 receptor-mediated mechanisms since Se-PTC
consistently inhibited phorbol myristate acetate and bradykinin-
mediated nociception. Additionally, it was reported that other
organoselenium compounds (diphenyl diselenide, bis selenide and
3-alkynyl selenophene) inhibited the nociception induced by brady-
kinin and phorbol myristate acetate (Jesse et al., 2009a,b; Savegnago
et al., 2007a; Wilhelm et al., 2009). Several studies have also
demonstrated the peripheral involvement of protein kinases A and
C in a number of persistent pain models (Cunha et al., 1999, 2004;
175N.F. Pavin et al. / European Journal of Pharmacology 668 (2011) 169–176Joseph and Levine, 2003; Souza et al., 2002). Based on this evidence,
we sought to determine whether Se-PTC could inhibit the nociceptive
response caused by 8-Bromo-cAMP, a known protein kinase A
activator. The results demonstrated that Se-PTC produced a signiﬁcant
inhibition in the licking response. Moreover, protein kinase A
phosphorylates calcium channels, glutamate receptors, and the cyclic
AMP response element-binding protein (Hell et al., 1995). Protein
kinase A was also involved in the antinociceptive mechanisms of
organoselenium compounds such as, p-methoxyl-diphenyl diselenide
and 3-alkynyl selenophene (Pinto et al., 2008; Wilhelm et al., 2009).
Se-PTC caused a prolonged latency period, indicating an increase in
the nociceptive threshold observed in the two thermal tests (tail-
immersion and hot-plate) of nociception used in this study. These tests
have beenwidely used as experimentalmodels tomeasure nociception,
especially for the screening of analgesic drugs (Dewey et al., 1969). The
response to the tail-immersion test is a spinal reﬂex, but may also
involve higher neural structures (Jensen andYaksh, 1986). The hot plate
test used in this study produces two kinds of behavioral response,
namely paw licking and jumping. Both of these are considered to be
supraspinally integrated responses (Chapman et al., 1985). In this study,
involvementof the opioid system in the antinociceptive action of Se-PTC
was evaluated in the tail-immersion test. Pretreatment of animals with
naloxone (anonselective opioid receptor antagonist) did not reverse the
antinociceptive effect caused by Se-PTC, demonstrating that the opioid
system is not involved in this effect. Moreover, morphine was more
potent than Se-PTC, however, several studies have reported drugs with
less potency than morphine in the tail-ﬂick and hot-plate tests (Silbert
et al., 1991; Vazet al., 1996). In accordancewith these results,wedid not
observe any opioid system involvement in the antinociceptive effect of
other organoselenium compounds (Savegnago et al., 2007a; Pinto et al.,
2008; Luchese et al., 2010).
Pretreatment of mice with Se-PTC produced an anti-hypernocicep-
tive effect for up to 4 h in the carrageenan acute model of nociception.
The carrageenan-induced hypernociception model has been widely
employed in assessing the effects of new anti-inﬂammatory drugs
(Posadas et al., 2004; Quintão et al., 2005). Carrageenan causes an
inﬂammatory response, accompanied by cell migration and release of
inﬂammatory mediators (such as prostaglandins, histamine, glutamate
and substance P). It is accepted that neutrophils release cytotoxic
enzymes and reactive oxygen specieswith a consequent exacerbation of
inﬂammatory conditions (Calixto et al., 2001). Additionally, it is known
that the sensitization of nociceptors (hypernociception) induced by
carrageenan is a metabotropic event involving stimulation of the cyclic
AMP-dependent protein kinase A or phospholipase-protein kinase C
pathways (Cunha et al., 1999; Taiwo and Levine, 1989). This suggests
that Se-PTCmay produce its antinociceptive effects by interrupting such
pathways.
It was observed that Se-PTCwas effective against Complete Freund's
Adjuvant-induced inﬂammatory nociception. Persistent nociception
resulting from the peripheral injection of Complete Freund's
Adjuvant leads to the release of multiple inﬂammatory and
nociceptive mediators, resulting in increased long-lasting discharge
of primary sensory ﬁbers that modify the neuronal, neuroglial and
neuro-immune cell phenotype and function of the central nervous
system (Quintão et al., 2005). In addition, the anti-hyperalgesic effect
of Se-PTC appeared 30 min post-administration and was maintained
for up to 4 h. Similarly to Se-PTC, dipyrone is effective up to 4 h after
its administration, while morphine produces an anti-hyperalgesic
effect that is maintained for up to 6 h (Milano et al., 2008). Of
note, we reported previously that other organoselenium compounds
(diphenyl diselenide and 3-alkynyl selenophene) produced anti-
hypernociceptive effects against Complete Freund's Adjuvant-in-
duced inﬂammatory nociception in mice (Savegnago et al., 2007b;
Wilhelm et al., 2009).
In conclusion, these ﬁndings demonstrates that Se-PTC suppressed
the nociceptive behavior associatedwith acute inﬂammation andmayhave a beneﬁcial role in the treatment of inﬂammatory pain.
Furthermore, Se-PTC did not modify any biochemical parameters or
locomotor and exploratory activities in mice. Se-PTC appeared to
modulate the activation of nociceptors by bradykinin, transient
receptor potential agonists (i.e. cinnamaldehyde and capsaicin) and
glutamatergic agonists (i.e. NMDA and trans-ACPD). Moreover, Se-
PTC may have prevented the sensitization process in peripheral
nociceptors through protein kinase A and C signaling pathways. It is
proposed that Se-PTC has a potential application in the ongoing
development of new clinically relevant drugs for pain management.
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